- Entry
- $2.57
- Now
- $2.21 -14.0%
- Target
- $26.00
- Score
- —
H.C. Wainwright analyst maintained a Buy rating on Bioline RX Ltd Sponsored ADR yesterday and set a price target of $26.00. Joseph Pantginis has given his Buy rating due to a combination of factors highlighting Bioline RX’s advancing pipeline and upcoming catalysts. He notes that the first-in-class DDR agent GLIX1 is progressing through a Phase 1/2a trial in glioblastoma, with multiple dose-escalation cohorts planned and a Phase 2a expansion design that targets both GBM and additional tumor types, including a …
— ORIGINAL POST ·
Joseph Pantginis Reiterates Buy on $BLRX (BiolineRX) as GLIX1 and CheMo4METPANC Advance and APHEXDA Royalties Support Funding Through 1H 2027
· r/pennystocks
· Sep 2, 2026